Objectives: Epidemiologic studies have confirmed that major depression (MD) is an extremely common condition, but also one that is associated with an unexpectedly broad spectrum of morbidity. It is no longer a tenable position to regard MD as being a simple indicator of treatment need, nor is a one-size-fits-all approach to treatment likely to be an effective guide to health care delivery. The objective of this commentary is to explore the implications of these new epidemiologic findings for policy and practice in Canada.
have advanced the state of knowledge about this disorder's prevalence and the adequacy of its management in the population. The evolving understanding of depression epidemiology is beginning to influence clinical practice guidelines, particularly those put forward by NICE in the United Kingdom. 1 However, there has not been widespread dissemination of these ideas in the Canadian system, nor are the NICE guidelines commonly used in Canada. A point of departure between the NICE guidelines and the 2001 Canadian Network for Mood and Anxiety Treatment guidelines is the role of watchful waiting. In NICE, watchful waiting is recommended for mild episodes of depression, whereas the 2001 Canadian Network for Mood and Anxiety Treatment guidelines treat the diagnosis of MD as a de facto indictor of treatment need. 2 The NICE guidelines' reference to depressive disorders uses the ICD-10 approach, 3 which differs from the DSM-IV. In ICD-10, a depressive episode must include at least 2 out of 3 specified symptoms: depressed mood, loss of interest or pleasure, and decreased energy, and a total of only 4 symptoms are needed to meet the requirement for a mild episode. In contrast, DSM-IV requires 1 of its 2 key symptoms (depressed mood, diminished interest or pleasure) and a total of 5 symptoms. 4 ICD-10 criteria captures a broader range of morbidity than DSM-IV. Moderate depressive episode in ICD-10 requires that at least 6 depressive symptoms be present. 3 The differences in clinical practice guidelines may, in part, derive from these differences in diagnostic definitions. However, there is growing evidence that, irrespective of the diagnostic definitions employed, depressive morbidity occurs across a broader spectrum of severity and prognosis than was previously believed. A one-size-fits-all approach to practice and policy for this condition increasingly seems ill-advised. This commentary will briefly summarize recent developments in depression epidemiology, and will seek to identify the resulting implications for clinical practice, health policy, and future depression research.
Epidemiologic Findings
Both DSM-IV and ICD-10 criteria provide operational definitions of a syndrome of depression-major depressive episode in DSM-IV 4 and depressive episode in ICD-10. 3 These episode-based definitions are the building blocks of diagnoses for mood (DSM-IV) and affective (ICD-10) disorders. These diagnoses are nominal categories with utility for clinical practice. For example, such categories serve to enhance clinical communication and help to link practice to research and education. 4 The diagnostic definitions provided by DSM-IV and ICD-10 are generally viewed as more useful in clinical practice than are ordinal ratings of depressive symptoms provided by rating scales. According to DSM-IV, the naming of categories is a "fundamental approach used in all systems of medical diagnosis." 4 Diagnostic categories are also more effective than ordinal scales at differentiating normal experience from clinically relevant disorders. The effectiveness of a diagnostic definition in this regard is not solely related to the occurrence of symptoms but also to requirements for specific symptoms, requirements that symptoms exceed thresholds of severity and persistence, and exclusion criteria to help differentiate a specified syndrome from other categories, for example, distinguishing MD from bereavement. According to DSM-IV, dimensional scales are less familiar and less vivid than nominal categories and have been less useful in clinical practice and in stimulating research. 4 On the surface, it appears plausible that DSM-IV criteria could act as a definition of treatment need. This is especially true when one considers that the general concept of a mental disorder in DSM-IV requires that the disorder be characterized by distress or disability, or that there be a significantly increased risk of suffering death, pain, disability, or an important loss of freedom. 4 Indeed, there is some evidence that patients in psychiatric settings who fulfill criteria for MD almost always have clinically significant disorders. A recent clinical study investigating the impact of applying a clinical significance item to syndromal data found that the application made little difference. 5 All patients meeting DSM-IV criteria for MD in the psychiatric clinic where this study was conducted had clinically significant disorders. However, in community populations, a more complex situation exists. Here, the application of items assessing clinical significance makes a large difference on who is classified as a case. 6 Some individuals who would be classified as having a depressive disorder in the community by application of DSM-IV diagnostic criteria, have syndromes that are mild and often self-limited. 7 How is it possible that application of the same sets of diagnostic criteria in clinical and community populations could identify cases that are almost always clinically significant in the former but not necessarily in the latter? At least 4 factors appear to play a role including episode duration. Data from several studies point toward a particular pattern of recovery from major depressive episodes: there is a high probability of recovery early in episodes and this declines over time. 8, 9 In the Canadian Community Health Survey, the reported duration of first major depressive episodes in respondents with recurrent disorders was 2 weeks in 16% and one month or less in 30% 9 of the episodes. Brief episodes are unlikely to be represented in clinical settings because of the need for making appointments, referrals, and so on, even if care were immediately sought. A second factor concerns the spectrum of expression of depressive symptoms and their relation to life events. With its exclusion for bereavement, DSM-IV acknowledges that even severe depressive syndromes can be an aspect of normal emotional experience. However, the somewhat arbitrary lack of a comparable exclusion criterion for other types of losses and threats indicates that individuals with reactions that may be comparable with bereavement meet DSM-IV criteria for MD. 10 A third consideration is the issue of recall bias. Many episodes of MD appear to be forgotten later in life, 11 which means that most or all epidemiologic estimates of MD lifetime prevalence are probably underestimates. Having an episode of MD at some time in one's life may actually be the norm rather than the exception. 12 Fourth, in epidemiologic research, diagnoses are almost always made using fully structured diagnostic interviews. These do not permit any role for clinical judgment in diagnosis. This is another factor that may lead to differences between clinical cases and those detected by epidemiologic studies: patients referred to psychiatrists have already been judged by a referring professional to have a clinically significant health problem. In summary, while diagnostic criteria for MD are helpful for distinguishing normal emotional responses from clinically significant disorders, they are not completely effective in this regard. In community populations, a sizable proportion of individuals meeting diagnostic criteria for mood disorders may not need intensive treatment and some proportion of them may not need any intervention at all.
It may be possible to improve the usefulness of diagnostic criteria as proxy indicators for treatment need by revising criteria in future diagnostic manuals. By adding clinical significance criteria making reference to distress and dysfunction, DSM-IV has already attempted to apply a higher diagnostic threshold than symptoms themselves would supply. However, it seems likely that factors determining treatment need are sufficiently diverse and subtle to preclude the success of this strategy. For example, distress (a cardinal indicator of clinical significance in DSM-IV) is a subjective factor that may be altered in its expression by characterological, cultural, or linguistic factors. Further, intense distress can occur in contexts where this is not pathological, for example, bereavement, and related syndromes. The extent to which depression causes dysfunction (another key indicator in DSM-IV) may depend on the sort of functional demands under which an individual operates. Comorbidity may contribute both to distress and dysfunction in ways that preclude disentangling the effects of depression from those of comorbid conditions. Consistent with these ideas, Beals et al 13 have shown that raising threshold requirements for clinical significance appears to improve specificity, but only at the expense of larger offsetting losses in sensitivity.
Whereas many episodes of MD may be self-limited and not necessarily clinically significant, it is also true that many episodes of subthreshold depression may be clinically significant. 14 Horwitz and Wakefield 15 argue that the context in which an episode occurs is therefore of particular importance in determining when a diagnosis is warranted. In clinical settings, there is an opportunity to explore the impact of symptoms on all aspects of patients' lives, so that clinical judgment can be brought to bear on questions concerning clinical significance. However, it may be unrealistic to expect that diagnostic criteria in isolation can adequately encompass these judgments, particularly in community studies.
In summary, MD is probably more common than has previously been suspected, but the condition also manifests across a broader range of morbidity than was previously believed. For both reasons, the syndrome considered in isolation is probably a poor indicator of treatment need in community populations. Nevertheless, there has been a tendency to regard untreated MD as a metric for unmet need in the population. [16] [17] [18] In fact, this tendency has probably had some positive impact. By drawing attention to the issue of undertreatment, the epidemiologic literature has stimulated interest in improving access to treatment and may have contributed to the increases in AD use that have occurred in Canada [19] [20] [21] and elsewhere. 22, 23 However, there may also have been negative impacts, such as discouraging interest in strategies, including watchful waiting or cognitivebehavioural self-management strategies, and potentially even encouraging overtreatment. Although rarely discussed in the psychiatric literature, overtreatment may be an important issue in milder cases, where the potential benefits of AD treatment may sometimes be outweighed by financial costs and risk of side effects. 1 Evidence also suggests that patients with minor depression and adjustment disorders are frequently treated with ADs, which may represent overuse as there is little evidence of effectiveness of medication in these populations. 24
Implications for Screening
The US Preventive Services Task Force recommends that all adults be screened for depression in primary care. 25 In contrast, the NICE guidelines recommend that screening be restricted to high-risk groups. 1 These differences reflect a different set of judgments about the base rate issue that is central to all screening initiatives. Application of a screening test in a population with a higher pretest probability will lead (at any given level of sensitivity and specificity) to a higher positive predictive value. The NICE approach may result in a higher likelihood that a patient who screens positive actually has MD but also in an increased likelihood that cases in low-risk groups will be undetected.
An important implication of the baseline issue is that the impact of screening is likely to be dependent on the context in which it occurs. False positive screen results will be most troublesome in general population screening initiatives, as base rates are lower in community than in clinical populations. As it appears that some proportion of individuals meeting diagnostic definitions for depressive disorders do not have treatment needs, even true positive results could result in a diversion of resources away from those who need them the most. On the other hand, strategies such as watchful waiting and stepped care that start with self-management may allow screening efforts to better meet patients' needs without incurring the risks or expense associated with unnecessary pharmacologic treatment. By allowing screening test thresholds to be lower (and with higher sensitivity), such strategies, effectively implemented, may allow existing resources to reach more individuals without incurring risks and inefficiencies that might ordinarily result from screening. Such questions deserve, but have not received, careful attention in research.
As MD appears to encompass a very broad range of morbidity, it would seem valuable for practice settings that engage in screening activities to have adequate resources to carry out an individualized clinical assessment of the needs, if any, of screen-positive patients. The duration of symptoms (a variable that is not assessed by any screening instrument currently available) and demographic predictors such as comorbid physical illness, lack of social support, severity of depression, and having had previous long episodes are all associated with increased duration of an index major depressive episode. 26 The severity of symptoms, the extent of distress associated with them, the functional impact that they cause, and their dangerousness are other relevant considerations. However, it should be emphasized that the issue of resource allocation associated with post-screening clinical assessment is not a trivial one. One study that examined a popular 2-item screen using the first 2 questions from the Patient Health Questionnaire found that 49.4% of primary care patients screened positive, yet only 31% of these individuals had a depressive disorder according to the Composite International Diagnostic Interview. 27
Implications for Treatment
The broad spectrum of morbidity associated with major depressive syndrome creates a necessity that clinical settings should be able to offer a commensurate spectrum of services, that is, a stepped-care approach to service delivery. The option of ignoring depression is not recommended by any set of guidelines. However, the strategy of watchful waiting is incorporated into the NICE guidelines. 1 This consists of arranging an additional assessment, generally within 2 weeks to determine whether recovery without intervention has occurred. The NICE guidelines also refer to guided self-help programs based on cognitive-behavioural therapy. Materials for guided self-management are increasingly available, both in the form of booklets and toolkits 28, 29 and online interactive programs. 30 The NICE guidelines identify psychological treatment specifically focused on depression, such as problem solving therapy and brief CBT, as treatment options for mild and moderate depression. 31 According to Bilsker et al, 32 nearly 10% of the population visit a physician for depression in a given year, yet most receive less than 3 visits. An inadequate number of visits, relative to clinical practice guideline recommendations, has been regarded as an indication of inadequate treatment by some authors. 18 However, it may often represent the realities of depression epidemiology, as described above. As the number of visits is small, and because many of the visits likely involve short-lived episodes, supported self-management may be one of the best ways to improve service delivery to this segment of the population.
Implications for Policy
Recent developments in the United Kingdom help to show how these findings might be translated into health care policy. In a recently negotiated contract between the national government and the body representing primary care physicians it was determined that remuneration will be partially dependent on practicing in a manner consistent with the NICE depression guidelines. 33 First, primary care practices are expected to assess the severity of all patients who have had a diagnosis of depression, using 1 of 3 validated questionnaires: Patient Health Questionnaire-9, Beck-II, or the Hospital Anxiety and Depression Scale. The stepped-care approach requires an explicit assessment of severity, so that an appropriate intervention can be offered. This might range from watchful waiting, to active review and self-help, to brief psychological interventions, to treatment with an AD, to hospitalization. 1 Second, practices are expected to provide mildly depressed patients with access to self-help materials (in written or computerized form). Third, as a separate program sponsored by the UK Department of Health, there are a number of sites, currently 12, developing Improved Access to Psychological Therapies. 34 These involve working across primary and secondary mental health services to provide psychological services for individuals with depression, whether mild, moderate, or severe. The implementation of this approach requires coordination between the primary care contract (which provides incentives for accurate assessment of severity of depression), and providing an appropriate psychological intervention, through the Improving Access to Psychological Therapies program.
If one accepts that the evolving state of knowledge about MD epidemiology is consistent with the goals of the United Kingdom reforms, this does not necessarily provide clear direction for health systems in Canada. Primary care physicians may not have sufficient time for new types of involvement, and the complexity of administering stepped-care represents another obstacle.
The United Kingdom's health care system has features not found in Canada, for example, the crucial role of primary care trusts in monitoring accountability and consistency of practice. Nonetheless, we should consider how stepped-care approaches to depression could be implemented in Canada. Examples of stepped-care implementation in the Canadian health care system might include: providing depression self-management materials through health care authorities, delivering pragmatic training in supported self-management to primary care physicians, increasing the availability of cost-effective cognitive-behavioural therapy group treatment, and enhancing family practice practitioners' capacity to assess and treat depression in terms of severity level and pattern of previous episodes.
Further, the evolving understanding of MD epidemiology is not completely consistent with the belief, prominent in the literature during the past decade, that efforts to improve population-based care delivery should focus exclusively on the primary care setting. Since many episodes may be brief, and amenable to guided self-management (which implies that a health care professional acts as a guide), it is conceivable that public health interventions could productively target the general population itself. This is, in fact, occurring in many parts of the world, often as an internet-based outreach activity of specialized clinical centres. An example is the Mood Gym program developed at the Australian National University. After publication of a randomized controlled trial, 30 the program was made freely available on the web. This program differs from guided self-management in the sense that it can be self-guided.
Implications for Depression Research
An evolving understanding of MD epidemiology is increasingly pointing toward a need to rethink intervention strategies, but rethinking will not be enough and implementation of changes should be guided by evidence. This research agenda should avoid any one size fits all perspective. Recently, there has been a shift in thinking about MD from an acute care model toward a chronic disease model. 35, 36 This shift in thinking represents the epidemiological reality that MD can be a chronic and recurrent condition, but risks adoption of an alternative model that also may fail to respect the very broad spectrum of morbidity seen with this condition.
If one of the lessons of epidemiological research in the past decade is that the spectrum of morbidity associated with MD is unexpectedly broad, then further epidemiologic research will be needed in order to characterize this spectrum. While it is clear that many episodes are brief, the recurrence pattern and level of symptom burden between these episodes needs further exploration.
Whereas the strategy of watchful waiting in primary care is consistent with epidemiologic data, the safety and cost-effectiveness of this approach will require evaluation in the Canadian context. Further, clinical trials are needed to evaluate both the effectiveness and cost-effectiveness of guided self-care strategies in primary care. The existing therapeutics literature certainly provides a basis for optimism about the potential effectiveness of low-cost nonpharmacologic approaches at the mild end of the severity spectrum.
Stepped care involves a coordination of primary and specialist care. In the disease management approaches that have been extensively evaluated in the United States, this usually implies interaction between a depression case manager and psychiatrist, 37 but in Canada, the emphasis has been on shared care between a primary care professional and mental health care specialists. Shared care often involves placement of mental health professionals in primary care practices, but, unlike chronic disease management strategies, the shared care philosophy conveys no definite implications for activities such as screening or guided self-management. As a result, shared care does not necessarily lead to more effective stepped care. In Canada, the effectiveness and costeffectiveness of stepped-care approaches in primary care in general, and in primary care practices employing shared mental health care in particular, require further evaluation.
Many regional health authorities and governments in Canada offer health information directly to the public on their websites, which often include information on depression. Outreach activities may someday be able to assume a role as one of several first steps into a stepped-care system. For example, by facilitating access to rating instruments and self-help materials it may be possible to make more informed personal decisions about whether and how to seek care. Intuition suggests that such activities should be integrated with health care systems, rather than operating as stand-alone initiatives, yet research is required to identify models for doing so, and to assess the safety and usefulness of such initiatives. 
Résumé : L'évolution de la compréhension de l'épidémiologie de la dépression majeure : les implications pour la pratique et les politiques
Objectifs : Les études épidémiologiques ont confirmé que la dépression majeure (DM) est une affection extrêmement répandue, mais qu'elle est également associée à un spectre de morbidité inopinément large. La position consistant à voir la DM comme un simple indicateur du besoin de traitement n'est plus défendable, et l'approche uniformisée du traitement n'est pas apte à guider efficacement la prestation des soins de santé. L'objectif de ce commentaire est d'explorer les implications de ces nouveaux résultats épidémiologiques pour les politiques et la pratique au Canada.
Méthode : Cet article est une étude sélective et un commentaire.
Résultats : Alors que les besoins de traitement actif et à long terme d'un sous-ensemble de personnes souffrant de DM ont reçu beaucoup d'attention dans la documentation, les besoins d'autres groupes n'ont pas fait l'objet de la même attention. Une bonne proportion de personnes ayant des épisodes qui satisfont à la définition du DSM-IV dans les populations des collectivités n'ont peut-être pas besoin du traitement intensif prôné par les guides de la pratique canadiens actuels. La stratégie d'attente supervisée peut avoir sa place dans les soins primaires. Du côté des politiques, les stratégies de prise en charge guidée et peut-être autoguidée méritent plus d'attention qu'elles n'en ont reçue. Les stratégies de soins par paliers sont une option attrayante, mais la façon de les mettre en oeuvre le plus efficacement possible dans le contexte canadien est encore mal définie.
Conclusions : Le spectre de morbidité chez les personnes souffrant de DM dans les populations des collectivités est beaucoup plus large que ce qui avait été estimé antérieurement. Le système de santé devrait répondre par une gamme de services appropriée, mais bien des questions demeurent sur la façon de procéder.
